 | Up a level |
Journal Article
Barbui, T., Thiele, J., Carobbio, A., Vannucchi, A. M. and Tefferi, A. (2015). The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. Leukemia, 29 (4). S. 992 - 994. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Barbui, T., Thiele, J., Carobbio, A., Vannucchi, A. M. and Tefferi, A. (2015). The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. Leukemia, 29 (4). S. 992 - 994. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Vannucchi, A. M. and Tefferi, A. (2016). The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev., 30 (6). S. 453 - 460. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-1681
Barbui, T., Thiele, J., Kvasnicka, H. M., Carobbio, A., Vannucchi, A. M. and Tefferi, A. (2014). Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia, 28 (10). S. 2092 - 2096. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Barbui, T., Thiele, J., Vannucchi, A. M. and Tefferi, A. (2013). Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia, 27 (10). S. 1953 - 1959. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Barbui, T., Thiele, J., Vannucchi, A. M. and Tefferi, A. (2015). Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J., 5. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
Barbui, T., Thiele, J., Vannucchi, A. M. and Tefferi, A. (2014). Rethinking the diagnostic criteria of polycythemia vera. Leukemia, 28 (6). S. 1191 - 1196. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Gisslinger, H., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Falcone, C. and Tefferi, A. (2015). Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J., 5. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L. and Thiele, J. (2016). Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia, 30 (5). S. 1126 - 1133. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Gisslinger, H., Jeryczynski, G., Woelfler, A., Beham-Schmid, C. and Thiele, J. (2017). Response to Harrison et al.'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'. Leukemia, 31 (3). S. 768 - 771. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Jeryczynski, G., Albert, W., Gisslinger, B., Schalling, M., Burgstaller, S., Buxhofer-Ausch, V., Krauth, M. T., Geissler, K., Schloegl, E., Sliwa, T., Schiefer, A. I., Muellauer, L., Simonitsch-Klupp, I., Beham-Schmid, C., Thiele, J. and Gisslinger, H. (2016). A MULTICENTER EVALUATION OF THE REVISED 2015 WHO MINOR CRITERIA FOR PREFIBROTIC PRIMARY MYELOFIBROSIS. Haematologica, 101. S. 556 - 557. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jeryczynski, G., Gisslinger, B., Schalling, M., Muellauer, L., Schiefer, A. -I., Thiele, J. and Gisslinger, H. (2015). CLINICAL IMPACT OF BONE MARROW MORPHOLOGY FOR THE DIAGNOSIS OF ESSENTIAL THROMBOCYTHEMIA: COMPARISON BETWEEN THE BRITISH STANDARDS (BCSH) AND THE WHO CRITERIA. Haematologica, 100. S. 260 - 261. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Kroeger, N., Alchalby, H., Zabelina, T., Kvasnicka, H. M., Thiele, J., Buesche, G. and Kreipe, H. (2014). RAPID RESOLUTION OF BONE MARROW FIBROSIS ON DAY+100 PREDICTS OUTCOME AFTER ALLOGENEIC SCT IN MYELOFIBROSIS. Bone Marrow Transplant., 49. S. S146 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Kvasnicka, H. M., Thiele, J., Bueso-Ramos, C. E., Hasserjian, R. P., Gianelli, U., Van der Walt, J., Molina, T. J. and Orazi, A. (2014). Criteria for Therapy Response and Progression in Patients with Myelofibrosis Based on Bone Marrow Features. The International European LeukemiaNet Consensus Project. Lab. Invest., 94. S. 357A - 358. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1530-0307
Kvasnicka, H. M., Thiele, J., Bueso-Ramos, C. E., Hasserjian, R. P., Gianelli, U., Van der Walt, J., Molina, T. J. and Orazi, A. (2014). Criteria for Therapy Response and Progression in Patients with Myelofibrosis Based on Bone Marrow Features. The International European LeukemiaNet Consensus Project. Mod. Pathol., 27. S. 357A - 358. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1530-0285
Kvasnicka, H. M., Thiele, J., Bueso-Ramos, C. E., Sun, W., Cortes, J., Kantarjian, H. M. and Verstovsek, S. (2014). CHANGES IN BONE MARROW MORPHOLOGY IN PATIENTS WITH MYELOFIBROSIS TREATED FOR UP TO 5 YEARS WITH EITHER RUXOLITINIB OR BEST AVAILABLE THERAPY. Haematologica, 99. S. 127 - 129. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Pozdnyakova, O., Rodig, S., Bhandarkar, S., Wu, K., Thiele, J. and Hasserjian, R. (2015). The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. Leukemia, 29 (1). S. 241 - 246. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Pozdnyakova, O., Wu, K., Patki, A., Rodig, S. J., Thiele, J. and Hasserjian, R. (2014). High Concordance in Grading Reticulin Fibrosis and Hematopoietic Cellularity in Patients with Myeloproliferative Neoplasms Enrolled on Fedratinib (A JAK2 Inhibitor) Trials. Lab. Invest., 94. S. 371A - 373. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1530-0307
Pozdnyakova, O., Wu, K., Patki, A., Rodig, S. J., Thiele, J. and Hasserjian, R. (2014). High Concordance in Grading Reticulin Fibrosis and Hematopoietic Cellularity in Patients with Myeloproliferative Neoplasms Enrolled on Fedratinib (A JAK2 Inhibitor) Trials. Mod. Pathol., 27. S. 371A - 373. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1530-0285
Schalling, M., Gisslinger, B., Jeryczynski, G., Berg, T., Harutyunyan, A., Milosevic, J., Bagienski, K., Them, N., Schischlik, F., Buxhofer-Ausch, V., Nirnberger, G., Schiefer, A. -I., Muellauer, L., Kralovics, R., Thiele, J. and Gisslinger, H. (2015). IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION. Haematologica, 100. S. 262 - 263. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Skov, V., Burton, M., Thomassen, M., Larsen, T. Stauffer, Riley, C. Hasselbalch, Madelung, A. B., Kjaer, L., Bondo, H., Stamp, I., Ehinger, M., Dahl-Sorensen, R., Mortensen, N. B., Nielsen, K., Thiele, J., Jensen, M. K., Bjerrum, O. W., Kruse, T. A. and Hasselbalch, H. C. (2015). A 7-GENE SIGNATURE DEPICTS THE BIOCHEMICAL PROFILE OF EARLY PREFIBROTIC MYELOFIBROSIS. Haematologica, 100. S. 526 - 528. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Tefferi, A., Thiele, J., Vannucchi, A. M. and Barbui, T. (2014). An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia, 28 (7). S. 1407 - 1414. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Vannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J. -J., Kroeger, N., Thiele, J. and Buske, C. (2015). Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro). Ann. Oncol., 26. S. V85 - 15. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041